Peptide therapeutics for CNS indications
Abstract
Neuropeptides play a crucial role in the normal function of the central nervous system and peptide receptors hold great promise as therapeutic targets for the treatment of several CNS disorders. In general, the development of peptide therapeutics has been limited by the lack of drug-like properties of peptides and this has made it very difficult to transform them into marketable therapeutic molecules. Some of these challenges include poor in vivo stability, poor solubility, incompatibility with oral administration, shelf stability, cost of manufacture. Recent technical advances have overcome many of these limitations and have led to rapid growth in the development of peptides for a wide range of therapeutic indications such as diabetes, cancer and pain. This review examines the therapeutic potential of peptide agonists for the treatment of major CNS disorders such as schizophrenia, anxiety, depression and autism. Both clinical and preclinical data has been accumulated supporting the potential utility of agonists at central neurotensin, cholecystokinin, neuropeptide Y and oxytocin receptors. Some of the successful approaches that have been developed to increase the stability and longevity of peptides in vivo and improve their delivery are also described and potential strategies for overcoming the major challenge that is unique to CNS therapeutics, penetration of the blood-brain barrier, are discussed.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Several of the same peptides and their receptors that are released into the gut are also widely expressed in the brain or signal to the brain, where these peptides play well-established roles in the neurobiology of anxiety and depression.
“Of note, several of the same peptides and their receptors that are released into the gut are also widely expressed in the brain or signal to the brain, where these peptides play well-established roles in the neurobiology of anxiety and depression (for review, see [23,24]).”
From Anxiety, depression, and the microbiome: A role for gut peptides (2018) · cites this paper as [23]
Cites
Heinrichs, M., Baumgartner, T., Kirschbaum, C., & Ehlert, U. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00465-7 · Cited by 2,091 · see citing works
Oxytocin Modulates Neural Circuitry for Social Cognition and Fear in Humans
Kirsch, P., Esslinger, C., Chen, Q., Mier, D., Lis, S., Siddhanti, S., Gruppe, H., Mattay, V. S., Gallhofer, B., & Meyer-Lindenberg, A. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3984-05.2005 · Cited by 1,639 · see citing works
The neurobiology of pair bonding.
Young, L. J., & Wang, Z. (2004) · Nature Neuroscience · doi:10.1038/nn1327 · Cited by 1,523 · see citing works
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191 · see citing works
The anatomy of neuropeptide-y-containing neurons in rat brain
Chronwall, B. M., DiMaggio, D. A., Massari, V. J., Pickel, V. M., Ruggiero, D. A., & O’Donohue, T. L. (1985) · Neuroscience · doi:10.1016/0306-4522(85)90260-x · Cited by 1,088 · see citing works
Oxytocin in the Medial Amygdala is Essential for Social Recognition in the Mouse
Ferguson, J. N., Aldag, J. M., Insel, T. R., & Young, L. J. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-20-08278.2001 · Cited by 1,043 · see citing works
Kuter, D. J., Bussel, J. B., Lyons, R. M., Pullarkat, V. A., Gernsheimer, T., Senecal, F. M., Aledort, L. M., George, J. N., Kessler, C. M., Sanz, M. Á., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60203-2 · Cited by 871 · see citing works
Oxytocin receptor distribution reflects social organization in monogamous and polygamous voles
Insel, T. R., & Shapiro, L. E. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.13.5981 · Cited by 833 · see citing works
Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice
Takayanagi, Y., Yoshida, M., Bielsky, I. F., Ross, H. E., Kawamata, M., Onaka, T., Yanagisawa, T., Kimura, T., Matzuk, M. M., Young, L. J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505312102 · Cited by 806 · see citing works
Plasma oxytocin levels in autistic children
Modahl, C., Green, L. A., Fein, D., Morris, M., Waterhouse, L., Feinstein, C., & Levin, H. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00439-3 · Cited by 728 · see citing works
Biological actions of cholecystokinin
Crawley, J. N., & Corwin, R. L. (1994) · Peptides · doi:10.1016/0196-9781(94)90104-x · Cited by 713 · see citing works
Oxytocin Increases Retention of Social Cognition in Autism
Hollander, E., Bartz, J., Chaplin, W., Phillips, A., Sumner, J., Soorya, L., Anagnostou, E., & Wasserman, S. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.030 · Cited by 693 · see citing works
Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689 · see citing works
Strategies to improve plasma half life time of peptide and protein drugs
Werle, M., & Bernkop-Schnürch, A. (2006) · Amino Acids · doi:10.1007/s00726-005-0289-3 · Cited by 650 · see citing works
Demeule, M., Currie, J., Bertrand, Y., Ché, C., Nguyen, T., Régina, A., Gabathuler, R., Castaigne, J., & Béliveau, R. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05492.x · Cited by 557 · see citing works
Oxytocin Makes a Face in Memory Familiar
Rimmele, U., Hediger, K., Heinrichs, M., & Klaver, P. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.4260-08.2009 · Cited by 402 · see citing works
Heilig, M. A., S�derpalm, B., Engel, J. A., & Widerl�v, E. (1989) · Psychopharmacology · doi:10.1007/bf00441953 · Cited by 390 · see citing works
Loup, F., Tribollet, E., Dubois-Dauphin, M., & Dreifuss, J. J. (1991) · Brain Research · doi:10.1016/0006-8993(91)90345-v · Cited by 378 · see citing works
The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y
Kask, A., Harro, J., von Hörsten, S., Redrobe, J. P., Dumont, Y., & Quirion, R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(01)00066-5 · Cited by 358 · see citing works
Plasma oxytocin levels and anxiety in patients with major depression
Scantamburlo, G., Hansenne, M., Fuchs, S., Pitchot, W., Maréchal, P., Péqueux, C., Ansseau, M., & Legros, J. J. (2007) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2007.01.009 · Cited by 325 · see citing works
Ross, H. E., Freeman, S. M., Spiegel, L. L., Ren, X., Terwilliger, E. F., & Young, L. J. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5039-08.2009 · Cited by 322 · see citing works
Ring, R. H., Malberg, J. E., Potestio, L., Ping, J., Boikess, S., Luo, B., Schechter, L. E., Rizzo, S., Rahman, Z., & Rosenzweig-Lipson, S. (2006) · Psychopharmacology · doi:10.1007/s00213-005-0293-z · Cited by 319 · see citing works
Prausnitz, M. R., Mikszta, J. A., Cormier, M., & Andrianov, A. K. (2009) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-92165-3_18 · Cited by 318 · see citing works
Pardridge, W. M., Kang, Y., Buciak, J. L., & Yang, J. (1995) · Pharmaceutical Research · doi:10.1023/a:1016244500596 · Cited by 317 · see citing works
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
Feifel, D., Macdonald, K., Nguyen, A., Cobb, P., Warlan, H., Galangue, B., Minassian, A., Becker, O., Cooper, J., Perry, W., et al. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.039 · Cited by 308 · see citing works
Lee, H., Engelhardt, B., Lesley, J., Bickel, U., & Pardridge, W. M. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35388-1 · Cited by 287 · see citing works
Brain-specific expression of an exogenous gene after i.v. administration
Shi, N., Zhang, Y., Zhu, C., Boado, R. J., & Pardridge, W. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.221450098 · Cited by 273 · see citing works
Sajdyk, T. J., Vandergriff, M. G., & Gehlert, D. R. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00018-7 · Cited by 241 · see citing works
Neuroprotection with noninvasive neurotrophin delivery to the brain
Wu, D., & Pardridge, W. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.254 · Cited by 209 · see citing works
Redrobe, J. P. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00403-1 · Cited by 207 · see citing works
Global non-viral gene transfer to the primate brain following intravenous administration
Zhang, Y., Schlachetzki, F., & Pardridge, W. M. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00018-7 · Cited by 179 · see citing works
The role of amylin in the control of energy homeostasis
Lutz, T. A. (2010) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00703.2009 · Cited by 176 · see citing works
Genes Controlling Affiliative Behavior as Candidate Genes for Autism
Yrigollen, C. M., Han, S. S., Kochetkova, A., Babitz, T., Chang, J. T., Volkmar, F. R., Leckman, J. F., & Grigorenko, E. L. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.11.015 · Cited by 172 · see citing works
Legros, J.-J. (2001) · Psychoneuroendocrinology · doi:10.1016/s0306-4530(01)00018-x · Cited by 159 · see citing works
A Peptide-Based Erythropoietin-Receptor Agonist for Pure Red-Cell Aplasia
Macdougall, I. C., Rossert, J., Casadevall, N., Stead, R. B., Duliège, A., Froissart, M., & Eckardt, K. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa074037 · Cited by 156 · see citing works
Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist
Ring, R. H., Schechter, L. E., Leonard, S. K., Dwyer, J. M., Platt, B. J., Graf, R., Grauer, S. M., Pulicicchio, C. M., Resnick, L., Rahman, Z. U., et al. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2009.07.016 · Cited by 144 · see citing works
Oxytocin antagonism alters rat dams' oral grooming and upright posturing over pups
Pedersen, C. A., & Boccia, M. L. (2003) · Physiology & Behavior · doi:10.1016/j.physbeh.2003.07.011 · Cited by 131 · see citing works
Neurotensin: Role in psychiatric and neurological diseases
Cáceda, R., Kinkead, B. L., & Nemeroff, C. B. (2006) · Peptides · doi:10.1016/j.peptides.2006.04.024 · Cited by 129 · see citing works
Polymodal dose-response curve for oxytocin in the social recognition test
Benelli, A., Bertolini, A., Poggioli, R., Menozzi, B., Basaglia, R., & Arletti, R. (1995) · Neuropeptides · doi:10.1016/0143-4179(95)90029-2 · Cited by 128 · see citing works
Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating
Feifel, D., & Reza, T. L. (1999) · Psychopharmacology · doi:10.1007/s002130050811 · Cited by 121 · see citing works
Husum, H., Mikkelsen, J. D., Hogg, S., Mathé, A. A., & Mørk, A. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00009-5 · Cited by 115 · see citing works
Brain Neuropeptide Υ (NPY) in Stress and Alcohol Dependence
Heilig, M. A., & Thorsell, A. (2002) · Reviews in the Neurosciences · doi:10.1515/revneuro.2002.13.1.85 · Cited by 114 · see citing works
DISTRIBUTION OF NEUROTENSIN AND ITS RECEPTOR IN THE CENTRAL NERVOUS SYSTEM
Uhl, G. R. (1982) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1982.tb31565.x · Cited by 108 · see citing works
Anxiolytic-like actions of centrally-administered neuropeptide Y, but not galanin, in C57BL/6J mice
Karlsson, R., Holmes, A., Heilig, M. A., & Crawley, J. N. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2004.12.009 · Cited by 102 · see citing works
Nikisch, G., Ågren, H., Eap, C. B., Czernik, A., Baumann, P., & Mathé, A. A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005158 · Cited by 98 · see citing works
Binder, E. B., Kinkead, B. L., Owens, M. J., & Nemeroff, C. B. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01211-2 · Cited by 96 · see citing works
Crawley, J. (1992) · Journal of Neuroscience · doi:10.1523/jneurosci.12-09-03380.1992 · Cited by 95 · see citing works
Cholecystokinin-octapeptide effects on conditioned-avoidance behavior, stereotypy and catalepsy
Cohen, S. L., Knight, M., Tamminga, C. A., & Chase, T. N. (1982) · European Journal of Pharmacology · doi:10.1016/0014-2999(82)90254-0 · Cited by 91 · see citing works
Vaccarino, F. J., & Rankin, J. (1989) · Behavioral Neuroscience · doi:10.1037//0735-7044.103.4.831 · Cited by 89 · see citing works
Katre, N. V., Asherman, J., Schaefer, H., & Hora, M. (1998) · Journal of Pharmaceutical Sciences · doi:10.1021/js980080t · Cited by 89 · see citing works
Boado, R. J., Zhang, Y., Zhang, Y., & Pardridge, W. M. (2007) · Biotechnology and Bioengineering · doi:10.1002/bit.21369 · Cited by 87 · see citing works
Fassio, A., Evans, G., Grisshammer, R., Bolam, J. P., Mimmack, M. L., & Emson, P. C. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00060-5 · Cited by 86 · see citing works
Oxytocin Receptor Distribution Reflects Social Organization in Monogamous and Polygamous Voles
SHAPIRO, L. E., & INSEL, T. R. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb34380.x · Cited by 84 · see citing works
Nikisch, G., & Mathé, A. A. (2008) · European Psychiatry · doi:10.1016/j.eurpsy.2008.03.003 · Cited by 78 · see citing works
Vaccarino, F. J., & Rankin, J. (1989) · Behavioral Neuroscience · doi:10.1037/0735-7044.103.4.831 · Cited by 77 · see citing works
Wu, D., & Pardridge, W. M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)20939-9 · Cited by 76 · see citing works
CCK-8 modulation of mesolimbic dopamine: Antagonism of amphetamine-stimulated behaviors
Schneider, L. H., Alpert, J. E., & Iversen, S. D. (1983) · Peptides · doi:10.1016/0196-9781(83)90031-1 · Cited by 75 · see citing works
Uvnäs‐Moberg, K., Alster, P., & Svensson, T. H. (1992) · Psychopharmacology · doi:10.1007/bf02247726 · Cited by 68 · see citing works
CCK peptides and mRNA in the human brain
Lindefors, N., Lindén, A., Brené, S., Sedvall, G., & PERSSON, H. (1993) · Progress in Neurobiology · doi:10.1016/0301-0082(93)90010-p · Cited by 65 · see citing works
Savasta, M., Ruberte, E., Palacios, J. M., & Mengod, G. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90063-8 · Cited by 63 · see citing works
Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier.
Kurihara, A., & Pardridge, W. M. (1999) · PubMed · Cited by 61 · see citing works
Green, B., Mooney, M., Gault, V., Irwin, N., Bailey, C., Harriott, P., Greer, B., O'Harte, F., & Flatt, P. (2004) · Journal of Endocrinology · doi:10.1677/joe.0.1800379 · Cited by 57 · see citing works
Implications of Amylin Receptor Agonism
Roth, J. D., Maier, H., Chen, S., & Roland, B. L. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.581 · Cited by 55 · see citing works
Breslin, N. A., Suddath, R. L., Bissette, G., Nemeroff, C. B., Lowrimore, P., & Weinberger, D. R. (1994) · Schizophrenia Research · doi:10.1016/0920-9964(94)90082-5 · Cited by 53 · see citing works
Cholecystokinin peptides, dopamine and schizophrenia — A review
Nair, N. P. V., Lal, S., & Bloom, D. M. (1985) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(85)90011-9 · Cited by 49 · see citing works
Prolonged systemic delivery of streptokinase using liposome
Kim, I., Choi, H., Choi, H., Kim, B., & Kim, C. (1998) · Archives of Pharmacal Research · doi:10.1007/bf02975283 · Cited by 44 · see citing works
The use of cholecystokinin in schizophrenia: a review
Montgomery, S., & Green, M. C. D. (1988) · Psychological Medicine · doi:10.1017/s0033291700008278 · Cited by 43 · see citing works
ZETLER, G. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90415-6 · Cited by 42 · see citing works
Feifel, D. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00041-4 · Cited by 42 · see citing works
Stachowiak, A., Macchi, C., Nussdorfer, G. G., & Malendowicz, L. K. (1995) · Research in Experimental Medicine · doi:10.1007/bf02576797 · Cited by 42 · see citing works
Goyal, S. N., Upadhya, M. A., Kokare, D. M., Bhisikar, S. M., & Subhedar, N. K. (2009) · Brain Research · doi:10.1016/j.brainres.2009.02.033 · Cited by 36 · see citing works
Tachikawa, H., Harada, S., Kawanishi, Y., Okubo, T., & Suzuki, T. (2001) · Psychiatry Research · doi:10.1016/s0165-1781(01)00276-1 · Cited by 34 · see citing works
Salhanick, A. I., Clairmont, K. B., Buckholz, T. M., Pellegrino, C. M., Ha, S., & Lumb, K. J. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.06.002 · Cited by 32 · see citing works
Extended release peptide delivery systems through the use of PLGA microsphere combinations
Burton, K. W., Shameem, M., Thanoo, B. C., & DeLuca, P. P. (2000) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856200743977 · Cited by 24 · see citing works
CCK in Cerebral Cortex and at the Spinal Levela
Hökfelt, T. G. M., Morino, P., Verge, V. M. K., Castel, M., Broberger, C., Zhang, X., Herrera‐Marschitz, M., Meana, J. J., Ungerstedt, U., Xu, X., et al. (1994) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1994.tb44062.x · Cited by 16 · see citing works
Synthesis and activity of new linear and cyclic peptide T derivatives.
Marastoni, M., Salvadori, S., Scaranari, V., Spisani, S., Reali, E., Traniello, S., & Tomatis, A. (1994) · PubMed · Cited by 8 · see citing works
Increasing the platelet count in chronic ITP
Nurden, A. T., & Nurden, P. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60178-6 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Anxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573 · see citing works
Neuropeptide Y: a stressful review
Reichmann, F., & Holzer, P. (2016) · Neuropeptides · doi:10.1016/j.npep.2015.09.008 · Cited by 490 · see citing works
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365 · see citing works
Intranasal Treatment of Central Nervous System Dysfunction in Humans
Chapman, C. D., Frey, W. H., Craft, S., Danielyan, L., Hallschmid, M., Schiöth, H. B., & Benedict, C. (2013) · Pharmaceutical Research · doi:10.1007/s11095-012-0915-1 · Cited by 310 · see citing works
MacDonald, K., & Feifel, D. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00035 · Cited by 181 · see citing works
Targeting the neuropeptide Y system in stress-related psychiatric disorders
Enman, N. M., Sabban, E. L., McGonigle, P., & Bockstaele, E. J. V. (2014) · Neurobiology of Stress · doi:10.1016/j.ynstr.2014.09.007 · Cited by 126 · see citing works
Self-citationRuigrok, M. J. R., & de Lange, E. C. M. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9724-x · Cited by 121 · see citing works
Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties
Demeule, M., Beaudet, N., Régina, A., Besserer‐Offroy, É., Murza, A., Tétreault, P., Belleville, K., Ché, C., Larocque, A., Thiot, C., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70647 · Cited by 117 · see citing works
Kovac, S., & Walker, M. C. (2013) · Neuropeptides · doi:10.1016/j.npep.2013.10.015 · Cited by 112 · see citing works
Maes, K., Smolders, I. J., Michotte, Y. M., & Eeckhaut, A. V. (2014) · Journal of Chromatography A · doi:10.1016/j.chroma.2014.06.072 · Cited by 101 · see citing works
Neuropeptides in gut-brain axis and their influence on host immunity and stress
Wei, P., Keller, C., & Li, L. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.02.018 · Cited by 94 · see citing works
Neuropeptide Y, resilience, and PTSD therapeutics
Kautz, M. M., Charney, D. S., & Murrough, J. W. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.061 · Cited by 90 · see citing works
Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols
Alabsi, W., Eedara, B. B., Encinas-Basurto, D., Polt, R. L., & Mansour, H. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091870 · Cited by 84 · see citing works
Banerjee, P., & Shanthi, C. (2012) · Process Biochemistry · doi:10.1016/j.procbio.2012.09.012 · Cited by 69 · see citing works
Smith, C. M., Walker, A. W., Hosken, I. T., Chua, B. E., Zhang, C., Haidar, M., & Gundlach, A. L. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00046 · Cited by 68 · see citing works
Nanotechnology for CNS delivery of bio-therapeutic agents
Shah, L. K., Yadav, S. K., & Amiji, M. M. (2013) · Drug Delivery and Translational Research · doi:10.1007/s13346-013-0133-3 · Cited by 64 · see citing works
Maes, K., Liefferinge, J. V., Viaene, J., Schoors, J. V., Wanseele, Y. V., Béchade, G., Chambers, E. E., Morren, H., Michotte, Y. M., Heyden, Y. V., et al. (2014) · Journal of Chromatography A · doi:10.1016/j.chroma.2014.07.086 · Cited by 50 · see citing works
The Role of Neuropeptides in Suicidal Behavior: A Systematic Review
Serafini, G., Pompili, M., Lindqvist, D., Dwivedi, Y. K., & Girardi, P. (2013) · BioMed Research International · doi:10.1155/2013/687575 · Cited by 49 · see citing works
Therapeutic Potential of Conopeptides
Schroeder, C. I., & Craik, D. J. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.70 · Cited by 47 · see citing works
Peptides with therapeutic potential in the venom of the scorpion Buthus martensii Karsch
Li, Z., Hu, P., Wu, W., & Wang, Y. (2019) · Peptides · doi:10.1016/j.peptides.2019.02.009 · Cited by 47 · see citing works
Neuropeptides and oligopeptidases in schizophrenia
Rodríguez, B., Nani, J. V. S., Almeida, P. G. C., Brietzke, E. M., Lee, R. S., & Hayashi, M. A. F. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.11.024 · Cited by 47 · see citing works
Higashida, H., Furuhara, K., Yamauchi, A.-M., Deguchi, K., Harashima, A., Munesue, S., Lopatina, O. L., Gerasimenko, M., Salmina, A. B., Zhang, J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07949-4 · Cited by 46 · see citing works
Hang, Z.-C., Lei, T., Zeng, Z.-H., Cai, S.-L., Bi, W.-Y., & Du, H. (2021) · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · doi:10.1016/j.biopha.2021.112343 · Cited by 39 · see citing works
D’Alessandro, A., Cervia, D., Catalani, E., Gevi, F., Zolla, L., & Casini, G. (2014) · Molecular BioSystems · doi:10.1039/c3mb70362b · Cited by 43 · see citing works
Joo, M.-K., Lee, J.-W., Woo, J., Kim, H. J., Kim, D., & Choi, J. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2319844 · Cited by 41 · see citing works
Brunzell, D. H., McIntosh, J. M., & Papke, R. L. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12421 · Cited by 40 · see citing works
Neuropeptide Systems and Schizophrenia
LaCrosse, A., & Olive, M. F. (2013) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527311312050010 · Cited by 39 · see citing works
Kang, Y. J., Park, D. C., Shin, H., Park, J., & Kang, S. (2012) · Biomacromolecules · doi:10.1021/bm301339s · Cited by 37 · see citing works
Transendothelial Transport and Its Role in Therapeutics
Upadhyay, R. K. (2014) · International Scholarly Research Notices · doi:10.1155/2014/309404 · Cited by 37 · see citing works
The ethics of neuroenhancement
Chatterjee, A. K. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53501-6.00027-5 · Cited by 36 · see citing works
Muscle weakness during aging: a deficiency state involving declining angiogenesis
Ambrose, C. T. (2015) · Ageing Research Reviews · doi:10.1016/j.arr.2015.03.005 · Cited by 36 · see citing works
Regional and Cellular Mapping of Sortilin Immunoreactivity in Adult Human Brain
Xu, S., Zhang, Q., Zhāng, Q., Wan, L., Jiang, J., Tu, T., Manavis, J., Pan, A., Cai, Y., & Yan, X. (2019) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2019.00031 · Cited by 28 · see citing works
Venom-derived modulators of epilepsy-related ion channels
Chow, C. Y., Absalom, N. L., Biggs, K. A., King, G. F., & Ma, L. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114043 · Cited by 28 · see citing works
Peptide Pills for Brain diseases? Reality and Future Perspectives
Serrano, D. R., & Lalatsa, A. (2013) · Therapeutic Delivery · doi:10.4155/tde.13.5 · Cited by 27 · see citing works
Oxtr/TRPV1 expression and acclimation of skeletal muscle to cold-stress in male mice
Conte, E., Romano, A., Bellis, M. D., de Ceglia, M., Carratù, M. R., Gaetani, S., Maqoud, F., Tricarico, D., & Camerino, C. (2021) · Journal of Endocrinology · doi:10.1530/joe-20-0346 · Cited by 22 · see citing works
Neuropeptide Y and Pain: Insights from Brain Research
Nelson, T. S., Allen, H. N., & Khanna, R. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00333 · Cited by 20 · see citing works
Tobinski, A.-M., & Rappeneau, V. (2021) · Pharmaceuticals · doi:10.3390/ph14080780 · Cited by 18 · see citing works
Microbial fluorescence sensing for human neurotensin receptor type 1 using Gα-engineered yeast cells
Ishii, J., Oda, A., Togawa, S., Fukao, A., Fujiwara, T., Ogino, C., & Kondo, A. (2013) · Analytical Biochemistry · doi:10.1016/j.ab.2013.10.016 · Cited by 18 · see citing works
Classification of Peptides According to their Blood-Brain Barrier Influx
Stalmans, S., Gevaert, B., Wynendaele, E., Nielandt, J., Tré, G. D., Peremans, K. Y., Burvenich, C., & Spiegeleer, B. M. J. D. (2015) · Protein and Peptide Letters · doi:10.2174/0929866522666150622101223 · Cited by 18 · see citing works
Lim, C., Lee, S., Shin, Y., Cho, S., Park, C., Shin, Y., Song, E. C., Kim, W. K., Ham, C., Kim, S. B., et al. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb01202f · Cited by 17 · see citing works
Rodrigues, J. P., Prajapati, N., DeCoster, M. A., Poh, S., & Murray, T. A. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.09.019 · Cited by 17 · see citing works
Maes, K., Béchade, G., Schoors, J. V., Wanseele, Y. V., Liefferinge, J. V., Michotte, Y. M., Harden, S. N., Chambers, E. E., Claereboudt, J., Smolders, I. J., et al. (2015) · Bioanalysis · doi:10.4155/bio.14.269 · Cited by 16 · see citing works
Cervia, D., & Casini, G. (2013) · Current Neuropharmacology · doi:10.2174/157015913804999423 · Cited by 16 · see citing works
Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog
Tétreault, P., Besserer‐Offroy, É., Brouillette, R. L., René, A., Murza, A., Fanelli, R., Kirby, K., Parent, A. J., Dubuc, I., Beaudet, N., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173174 · Cited by 16 · see citing works
Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia
Vivancos, M., Fanelli, R., Besserer‐Offroy, É., Beaulieu, S., Chartier, M., Rojas, M. R., Mona, C. E., Previti, S., Rémond, E., Longpré, J., et al. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113189 · Cited by 16 · see citing works
Emerging Perspectives on Prime Editor Delivery to the Brain
BenDavid, E., Ramezanian, S., Lu, Y., Rousseau, J., Schroeder, A., Lavertu, M., & Tremblay, J. P. (2024) · Pharmaceuticals · doi:10.3390/ph17060763 · Cited by 15 · see citing works
Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development
Reynolds, T., de Zafra, C., Kim, A., & Gelzleichter, T. R. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-394810-6.00001-0 · Cited by 15 · see citing works
PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study
Porcelli, S., Balzarro, B., Lee, S.-J., Han, C., Patkar, A. A., Pae, C., & Serretti, A. (2016) · Neuropsychobiology · doi:10.1159/000445295 · Cited by 15 · see citing works
Yoshitake, S., Ijiri, S., Kehr, J., & Yoshitake, T. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.12.011 · Cited by 14 · see citing works
Wang, C., Qiu, T.-T., Diao, Y.-X., Zhang, Y., & Gu, N. (2015) · Biochimie · doi:10.1016/j.biochi.2015.06.008 · Cited by 14 · see citing works
Oxytocin Involvement in Body Composition Unveils the True Identity of Oxytocin
Camerino, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126383 · Cited by 13 · see citing works
Kanada, Y., Katayama, A., Ikemoto, H., Takahashi, K., Tsukada, M., Nakamura, A., Ishino, S., Hisamitsu, T., & Sunagawa, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s156795 · Cited by 10 · see citing works
Desai, D., & Shende, P. K. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102594 · Cited by 10 · see citing works
Schirrmacher, R., Bernard‐Gauthier, V., Reader, A. J., Soucy, J., Schirrmacher, E. S., Wängler, B., & Wängler, C. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.128 · Cited by 10 · see citing works
Bongaerts, J., Segers, K., Oudenhove, L. V., Wanseele, Y. V., Hulle, M. V., Bundel, D. D., Mangelings, D., Smolders, I. J., Heyden, Y. V., & Eeckhaut, A. V. (2020) · Journal of Chromatography A · doi:10.1016/j.chroma.2020.461462 · Cited by 10 · see citing works
Wängler, C., Chowdhury, S. F., Höfner, G. C., Djurova, P., Purisima, E. O., Bartenstein, P., Wängler, B., Fricker, G., Wanner, K. T., & Schirrmacher, R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5004123 · Cited by 9 · see citing works
Singh, A. A., Khan, F., & Song, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26104707 · Cited by 8 · see citing works
Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10 · see citing works
Kaltashov, I. A., Bobst, C. E., Nguyen, S., & Wang, S. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.04.014 · Cited by 8 · see citing works
Ariawan, D., Thananthirige, K. P. M., El-Omar, A., van der Hoven, J., Genoud, S., Stefen, H., Fath, T., van Eersel, J., Ittner, L. M., & Tietz, O. (2024) · RSC Advances · doi:10.1039/d4ra05040a · Cited by 8 · see citing works
Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia
Ni, P., Tian, Y., Gu, X., Yang, L., Wei, J., Wang, Y., Zhao, L., Zhang, Y., Zhang, C., Li, L., et al. (2019) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2019.152114 · Cited by 7 · see citing works
19F-Labeled amino acids for NMR structure analysis of membrane-bound peptides
Komarov, I. V., Afonin, S., & Ulrich, A. S. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812733-9.00010-6 · Cited by 7 · see citing works
A Placebo-Controlled Crossover Trial of Gastrin-Releasing Peptide in Childhood Autism
Marchezan, J., Becker, M. M., Schwartsmann, G., Ohlweiler, L., Roesler, R., Renck, L. B., Gonçalves, M. M. M., Ranzan, J., & Riesgo, R. D. S. (2017) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000213 · Cited by 6 · see citing works
Dong, X., Zhao, J., Shen, Y., Sun, Q., Wu, X., Zhu, Y., Yu, L., & Zhao, Y. (2021) · Frontiers in Pediatrics · doi:10.3389/fped.2021.718704 · Cited by 6 · see citing works
Wanseele, Y. V., Viaene, J., den Borre, L. V., Dewachter, K., Heyden, Y. V., Smolders, I. J., & Eeckhaut, A. V. (2017) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2017.01.014 · Cited by 6 · see citing works
Schizophrenia and Other Psychoses
Lawrence, R. E., First, M. B., & Lieberman, J. A. (2015) · doi:10.1002/9781118753378.ch48 · Cited by 6 · see citing works
Dong, X., Sun, S., Li, J., Shen, S., Chen, W., Li, T., & Li, X. (2023) · PeerJ · doi:10.7717/peerj.15846 · Cited by 5 · see citing works
Becker, M. M., Riesgo, R. D. S., Roesler, R., Bosa, C. A., Ohlweiler, L., Backes, B., Endres, R. G., Zanon, R. B., Marchezan, J., & Schwartsmann, G. (2016) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000165 · Cited by 5 · see citing works
Oxytocin und die suchterhaltenden Mechanismen der Alkoholabhängigkeit
Faehrmann, T., Zernig, G., & Mechtcheriakov, S. (2017) · Neuropsychiatrie · doi:10.1007/s40211-017-0229-y · Cited by 5 · see citing works
cNPDB: A comprehensive empirical crustacean neuropeptide databasePreprint
Tran, V. N. H., Duong, T. U., Fields, L. G., Tourlouskis, K., Beaver, M., & Li, L. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.29.667494 · Cited by 5 · see citing works
Sun, W., Jin, T., Yang, H., Li, J., Tian, Q., Gao, J., Peng, R., Zhang, G., & Zhang, X. (2024) · Schizophrenia · doi:10.1038/s41537-023-00425-1 · Cited by 3 · see citing works
Akama, K., Shimajiri, Y., Kainou, K., Iwasaki, R., Nakao, R., Nikawa, T., & Nishikawa, A. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbab059 · Cited by 4 · see citing works
Chapter 25: Peptide Drug/Device Combinations
Uddin, S. (2020) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-31415-6_25 · Cited by 4 · see citing works
Shang, Y., Hao, W., Zhang, W., Ma, Y., Niu, X.-L., Wei, Z., Sun, S., & Xu, J. (2024) · LWT · doi:10.1016/j.lwt.2024.116685 · Cited by 3 · see citing works
Yuan, B.-Y., Liu, W.-Z., Wang, X., Zhang, Y., Yang, D.-J., & Wang, C. (2018) · Peptides · doi:10.1016/j.peptides.2018.07.004 · Cited by 3 · see citing works
Wang, S., Bobst, C. E., & Kaltashov, I. A. (2015) · European Journal of Mass Spectrometry · doi:10.1255/ejms.1365 · Cited by 3 · see citing works
Advances in Aerosol Formulation for Targeted Delivery of Therapeutic Agents from Nose to Brain
Verma, S., Sharma, P. K., & Malviya, R. (2024) · Current Drug Delivery · doi:10.2174/0115672018285350240227073607 · Cited by 2 · see citing works
Image-Guided Delivery of Therapeutics to the Brain
Shah, L. K., Iyer, A. K., Talekar, M., & Amiji, M. M. (2014) · Advances in delivery science and technology · doi:10.1007/978-3-319-11355-5_4 · Cited by 2 · see citing works
Merighi, A., Sbriz, M., & Lossi, L. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1839947 · Cited by 1 · see citing works
Singla, A., & Upadhyayula, S. (2021) · Springer eBooks · doi:10.1007/978-3-030-58675-1_129-1 · Cited by 1 · see citing works
Active Targeting of Nanomedicines
Serrano, D. R., Kara, A., Ramirez, B. I., Ramirez, I. O., Öngoren, B., & Lalatsa, A. (2024) · Springer eBooks · doi:10.1007/978-3-031-59478-6_14 · Cited by 1 · see citing works
Antidepressant-Antianxiety Agents
Baldessarini, R. J. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3710-9_4 · Cited by 1 · see citing works
Serafini, G., Lindqvist, D., Brundin, L., Dwivedi, Y., Girardi, P., & Amore, M. (2014) · Wiley eBooks · doi:10.1002/9783527684403.ch15
Tedesco, A. C., Castilho–Fernandes, A., & Lopes, T. G. (2013) · Vigilância Sanitária em Debate · doi:10.3395/vd.v1i4.98en
Ocitocina, um “medicamento” ainda em potencial terapêutico para distúrbios psiquiátricos
de Deus, D. M. V., & de Freitas, P. S. (2017) · REVISTA HUM@NAE
Malavolta, L., & Cabral, F. R. (2015) · doi:10.4155/fseb2013.14.283
Future perspective on peptide therapeutics
Manning, M., Misicka, A., Bańkowski, K., & Verlander, M. S. (2015) · doi:10.4155/fseb2013.14.104
Exploring Effects of Aza-Amino Acid Installation on the Secondary Structure of Peptides.
Willis, E. L. (2020) · NCSU Libraries Repository (North Carolina State University Libraries)
ADME of Biologicals and New Therapeutic Modalities
Foti, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00141-9
Serrano, D. R., & Lalatsa, A. (2013) · Springer eBooks · doi:10.1007/978-1-4614-9164-4_13
Singla, A., & Upadhyayula, S. (2022) · Springer eBooks · doi:10.1007/978-3-030-84205-5_129
Nasal Oxytocin’s Anticonvulsant Effects on Pentylenetetrazol- induced Convulsions in Rats
Bora, E. S., Erdoğan, M. A., Karaali, R., Çakır, A., & Erbaş, O. (2023) · International Journal of Pharmacology · doi:10.3923/ijp.2023.178.184
Development of Inhibitors of Amyloid Fibril Propagation
Bendifallah, M. (2019) · theses.fr (ABES) · doi:10.70675/a872e5bdzc153z41f4z9472z725fd78aab48
Nose-to-Brain Delivery of Biologicals
Torres, J., Correia, A. C., & Silva, A. C. (2025) · Springer handbooks · doi:10.1007/978-3-032-01636-2_8
Peptides and their ligands: A new frontier in immunomodulation
Arora, V., & Singh, P. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44631-3.00012-3
- Authors
- McGonigle, P.
- Affiliations
- Psychogenics (United States) (US)
- Corresponding author
- McGonigle, Paul
- Venue
- Biochemical Pharmacology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 83
- Issue
- 5
- Pages
- 559-566
- ISSN
- 0006-2952 (ISSN-L)
- OpenAlex
- W1977931911
- Cited by
- 95
- References
- 76
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 8 · 2023: 3 · 2022: 3 · 2021: 9 · 2020: 7 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 10 · 2014: 11 · 2013: 14 · 2012: 7
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Biochemical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chemical Synthesis and Analysis
- Social Sciences › Psychology › Social Psychology › Neuroendocrine regulation and behavior
- Keywords
- peptide therapeutics, neuropeptides, peptide receptors, central nervous system disorders, peptide agonists, cholecystokinin receptors, neuropeptide Y receptors, oxytocin receptor, blood-brain barrier penetration, peptide stability, peptide delivery, schizophrenia, anxiety, depression, autism spectrum disorder
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Central Nervous System Diseases, Humans, Peptides, Receptors, Peptide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
